Erratum: Monitoring the progression of Alzheimer's disease with τ-PET (Brain (2016) 139 (1318-1320) DOI: 10.1093/brain/aww057);Monitoring the progression of Alzheimer's disease with τ-PET

Brain

Volumn 139, Issue 5, 2016, Pages 1318-1320

  Thal, Dietmar Rudolf ^a,b   Vandenberghe, Rik ^a,b  

^a KU LEUVEN UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOMETHYLTRANSFERASE; FLORTAUCIPIR F 18; AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; BASAL GANGLION; BRAIN STEM; CEREBELLUM; CORTICOBASAL DEGENERATION; DISEASE COURSE; DISEASE SEVERITY; HUMAN; IN VIVO STUDY; MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLE; NEUROPIL THREAD; NOTE; PICK PRESENILE DEMENTIA; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; DISEASE EXACERBATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; DISEASE PROGRESSION; HUMANS; TAU PROTEINS;

EID: 84966605858     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awab036     Document Type: Erratum

References (10)

1. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112: 389-404.
2. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.
3. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathological process in Alzheimer's disease: age categories 1 year to 100 years. J Neuropathol Exp Neurol 2011; 70: 960-9.
4. Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, et al. 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med 2016; 57: 208-14.
5. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007; 27: 6174-84.
6. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013; 79: 1094-108.
7. Murray ME, Lowe VJ, Graff-Radford NR, Liesinger AM, Cannon A, Przybelski SA, et al. Clinicopathologic and 11CPittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain 2015; 138: 1370-81.
8. Schwarz A, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, et al. Regional profiles of the candidate tau PET ligand [18F]-AV-1541 recapitulate key features of Braak histopathological stages. Brain 2016; 139: 1544-55.
9. Thal DR, Beach TG, Zanette M, Heurling K, Chakrabarty A, Ismail A, et al. [18F]flutemetamol amyloid PET in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of Ab pathology. Alzheimers Dement 2015; 11: 975-85.
10. Thal DR, Rüb U, Orantes M, Braak H. Phases of Abeta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-800.